Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company's lead drug candidate, AT-007, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy, as well as novel dual PI3k inhibitors in preclinical development for orphan oncology indications.
View Top Employees from Applied Therapeutics IncWebsite | http://www.appliedtherapeutics.com |
Ticker | APLT |
Revenue | $3 million |
Employees | 1 (1 on RocketReach) |
Founded | 2016 |
Address | 545 5th Ave, Ste 1400, New York City, New York 10017, US |
Phone | (212) 220-9319 |
Technologies |
JavaScript,
HTML,
PHP
+31 more
(view full list)
|
Industry | Education, Organizations, Biotechnology, Drug Discovery |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 541712 Companies, NAICS Code 54171 Companies |
Looking for a particular Applied Therapeutics Inc employee's phone or email?
The Applied Therapeutics Inc annual revenue was $3 million in 2023.
Shoshana Shendelman is the CEO of Applied Therapeutics Inc.
1 people are employed at Applied Therapeutics Inc.
Applied Therapeutics Inc is based in New York City, New York.
The NAICS codes for Applied Therapeutics Inc are [541, 54, 5417, 541712, 54171].
The SIC codes for Applied Therapeutics Inc are [873, 87].